SAG
RNAC icon

SageView Advisory Group’s Cartesian Therapeutics RNAC Stock Holding History

SageView Advisory Group’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$22 Buy
+3
New +$24 ﹤0.01% 2586

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SageView Advisory Group's RNAC Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Cartesian Therapeutics (RNAC) in Q4 2025: 3 shares worth $22. The stake represents ﹤0.01% of the portfolio and ranks #2586 among its holdings.

67 funds tracked by Wall St. Rank hold RNAC as of Q4 2025.

  • SageView Advisory Group held 3 shares of Cartesian Therapeutics worth $22 as of Q4 2025.
  • Cartesian Therapeutics was a new SageView Advisory Group position in Q4 2025.
  • Cartesian Therapeutics made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2586 holding.
  • 67 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.